Endothelial cells, as well as their major products nitric oxide (NO) and prostacyclin, play a key role in the regulation of vascular homeostasis. Diabetes mellitus is an important risk factor for cardiovascular disease. Diabetes-induced endothelial dysfunction is a critical and initiating factor in the genesis of diabetic vascular complications. The present review focuses on both large blood vessels and the microvasculature. The endothelial dysfunction in diabetic macrovascular complications is characterized by reduced NO bioavailability, poorly compensated for by increased production of prostacyclin and/or endothelium-dependent hyperpolarizations, and increased production or action of endothelium-derived vasoconstrictors. The endothelial dysfunction of microvascular complications is primarily characterized by decreased release of NO, enhanced oxidative stress, increased production of inflammatory factors, abnormal angiogenesis, and impaired endothelial repair. In addition, non-coding RNAs (microRNAs) have emerged as participating in numerous cellular processes. Thus, this reviews pays special attention to microRNAs and their modulatory role in diabetes-induced vascular dysfunction. Some therapeutic strategies for preventing and restoring diabetic endothelial dysfunction are also highlighted.
Introduction
In 1980, Furchgott and Zawadzki reported that the endothelium, the innermost layer of the vascular wall, plays a crucial role in regulating local vascular tone. 1 Since then, the importance of the endothelium has been studied extensively under both physiological and pathological conditions. The obligatory roles of the endothelium include releasing endothelium-derived vasoactive factors, preventing platelet aggregation and leukocyte adhesion, and regulating cell proliferation. In blood vessels, endothelial nitric oxide synthase (eNOS; also known as nitric oxide synthase [NOS] III) is constitutively activated by laminar flow. Nitric oxide (NO) is the major endothelial regulator of local vascular tone and has inhibitory effects on the production and/or action of other vasoactive factors, such as vasoconstrictor prostanoids and endothelin-1 (ET-1). In the early stages of disease when NO-mediated responses are impaired, prostacyclin and/or endothelium-dependent hyperpolarization (EDH) help compensate for the impairment. Later, as the ability of the endothelial cells to release NO progressively decreases, the production of endothelium-derived, cyclo-oxygenase-dependent contracting factors (EDCF) and/or ET-1 becomes prominent, favoring vasoconstriction. Meanwhile, because the protective effects of NO recede, the protein expression of adhesion molecules (e.g. vascular cell adhesion molecule 1 , intercellular adhesion molecule 1 [ICAM-1], E-selectin) on endothelial cells is enhanced, facilitating leukocyte adhesion and penetration. The history of eNOS and the fate of its major product, NO, have been summarized elsewhere in detail. [2] [3] [4] Diabetes mellitus is a heterogeneous disorder of glucose metabolism. It has been estimated that the prevalence of diabetes for all age groups worldwide will increase from 2.8% in 2000 to 4.4% of the population in 2030 (366 million people). 5 In particular, endothelial dysfunction, an important cardiovascular risk factor, has been studied extensively in diabetic animals and humans because it is a critical and initiating factor in the genesis of vascular disease. 4 Diabetic macrovascular disease resembles atherosclerotic lesions both morphologically and functionally, whereas diabetic microvascular disease is present primarily as retinopathy, nephropathy, neuropathy, and vascular abnormalities in the lower extremities, 6 leading to visual impairment, kidney failure, stroke, diabetic cardiomyopathy, and lower extremity dysfunction, respectively. Hence, the present brief review focuses not only on large blood vessels, but also on the microvasculature. In addition, special attention is paid to microRNAs (miRNAs) and their modulating role in diabetes-induced vascular dysfunction, because these non-coding RNAs are involved in several pathological processes. 7, 8 Endothelial dysfunction in conduit and resistance arteries affects vasomotor responses Vascular functional studies are often performed ex vivo by measuring tension changes in blood vessel rings exposed to different agonists in the absence or presence of pharmacological antagonists. In such studies, arteries with a diameter >60 μm are suspended in 
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Figure 1
Diabetes reduces endothelium-dependent relaxations in conduit and resistance arteries. Diabetes-induced endothelial dysfunction presents itself as a reduced protein expression of endothelial nitric oxide synthase (eNOS), reduced phosphorylation of the active site of the eNOS (i.e. Ser organ chambers or myographs. Conduit arteries, including the aorta, carotid, femoral and main renal arteries, are used to study primarily NO-mediated relaxations, whereas mesenteric resistance arteries enable the role of EDH to be assessed because such responses play a more prominent role in smaller blood vessels. 9, 10 The aorta and the carotid arteries are the preparations of choice in which to study EDCFmediated contractions. 11, 12 Except for some earlier reports suggesting normal or enhanced endothelium-dependent relaxation, 13, 14 it has been consistently demonstrated that diabetes and/or hyperglycemia induce blunted endotheliumdependent relaxations in different vascular beds 15, 16 ( Fig. 1) . Reduced NO bioavailability is responsible in most of the cases of conduit arteries of diabetes because of reduced protein expression of eNOS, 17 reduced phosphorylation of the active site of the enzyme (i.e. Ser 1177 ), 18 increased phosphorylation of its inhibitory site (i.e. Thr 495 ), 18 decreased levels of the essential eNOS cofactor tetrahydrobiopterin, enhanced arginase activity (diverting the precursor L-arginine from eNOS), 19, 20 increased levels of the endogenous eNOS inhibitor asymmetric dimethylarginine (AMDA), 21 and enhanced production of oxygen-derived free radicals (scavenging NO). [22] [23] [24] Under physiological conditions, the vasodilator properties of prostacyclin are often masked or overwhelmed by those of NO. 2, 25 However, in diabetes, prostacyclin participates in acetylcholineinduced and endothelium-dependent relaxations of canine coronary arteries 26 and rat aorta. 27 In addition, impaired endothelium-dependent relaxations of aortas from type 1 diabetic (T1D) rats can be normalized by oral administration of prostacyclin analogs. 28 These data indicate that prostacyclin takes part in endothelium-dependent vasodilatation under diabetic conditions. In resistance arteries, EDH is an important compensatory player in diabetes. 10 Thus, in diabetic animals, EDH-mediated relaxations are depressed when the NO component is preserved, 29,30 whereas they are augmented when NO-mediated relaxations are reduced. 14, 31 Increased production of EDCF is a hallmark of endothelial dysfunction 12 (Fig. 2) . The exact cyclooxygenase products involved vary depending on the vascular bed examined, the experimental models studied, and the endothelium-dependent stimulating agonists applied, 4, [32] [33] [34] which include endoperoxides, thromboxane A 2 , prostaglandin E 2 and mainly prostacyclin when it reaches concentrations activating thromboxane prostanoid (TP) receptors on vascular smooth muscle cells. 12 The enhanced production of EDCF is linked to increased levels of oxidative stress, because reactive oxygen species (ROS) upregulate the expression of cyclo-oxygenase in endothelial cells, whereas the enzyme itself is one of the important sources of oxygenderived free radicals, initiating a vicious cycle. 16 In addition, oxygen radicals, such as superoxide anions and hydroxyl radicals, can contract vascular smooth muscle cells, thus acting as an EDCF. 35, 36 In diabetic animals, EDCF-mediated contractions are augmented in conduit arteries, including the aorta [37] [38] [39] and 
Figure 2
Diabetes stimulates the production and/or action of endothelium-derived cyclo-oxygenase-dependent contracting factor (EDCF) and endothelin (ET)-1. The vasoconstrictor prostanoids include endoperoxides, thromboxane A 2 , prostaglandin E 2 (PGE 2 ), and prostacyclin (PGI 2 ) when it reaches concentrations activating corresponding receptors on vascular smooth muscle cells. The enhanced production of EDCFs is linked to increased levels of oxidative stress, because reactive oxygen species upregulate the expression of cyclo-oxygenase (COX) in endothelial cells, whereas the enzyme itself is one of the important sources of oxygen-derived free radicals. Working together with EDCF, ET-1 enhances vasoconstriction and local inflammation in diabetes. AA, arachidonic acid; eNOS, endothelial nitric oxide synthase; EP, PGE 2 receptor; NO, nitric oxide; PGH 2 , prostaglandin H 2 ; R, receptor; TP, thromboxane receptor; TXB 2 , thromboxane B 2 .
femoral 40 and renal 41 arteries, as well as in mesenteric resistance arteries. 42, 43 Endothelin-1 is one of the most powerful endogenous vasoconstrictors. 44, 45 Hand-in-hand with EDCF, ET-1 enhances vasoconstriction and local inflammation 34 (Fig. 2) . Blockade of the ET-1 pathway reduces diabetes-induced oxidative stress in the vascular wall and improves endothelium-dependent relaxations in the rat cerebral vasculature, 46, 47 as well as in the forearm of diabetic patients with coronary disease. [48] [49] [50] Diabetes causes endothelial dysfunction in the microvasculature Arterioles or capillaries, which are devoid of vascular smooth muscle cells and thus cannot develop tension, are too small for their function to be tested in organ chambers or myographs. Hence, the degree of endothelial dysfunction (or of abnormal endothelial activation) in the microvasculature is usually estimated by measuring the expression of eNOS and adhesion molecules, the extent of penetration of white blood cells, changes in capillary density, and ultimately the appearance of lesions. 51, 52 In particular, diabetes disrupts the endothelial barriers (including the blood-brain, blood-retina and the glomerular barriers) by downregulating cell junction proteins (connexins 30.2 and 43, claudins-5 and -11, and zonular occludens-1 [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] ) and upregulating integrin expression, [66] [67] [68] which leads to vascular leakage and abnormal permeability. 69, 70 Several factors appear to contribute to diabetic microvascular endothelial dysfunction, as described below.
Shortage of NO
In line with the reduced NO bioavailability in larger blood vessels, eNOS expression and NO production are also reduced in the microvasculature (Fig. 3) . Thus, reduced eNOS expression is observed in cardiac tissue [71] [72] [73] [74] [75] and in cerebrovascular, 52 glomerular, [76] [77] [78] and retinal 79 endothelial cells of diabetic rodents. Mice with deletion of eNOS have increased levels of proinflammatory factors and advanced pathological changes in their kidneys. 80 Mice deficient in eNOS phosphorylation exhibit attenuated cerebrovascular function and increased infarct size. 81 Conversely, diabetic mice overexpressing eNOS have improved cerebrovascular reactivity, 82 and in diabetic animals increased levels of NO, whether produced endogenously or added exogenously, ameliorate cardiomyopathy, 83 reduce proteinuria, and preserve renal function, 84-86 as well as restoring ischemic hind limb blood flow.
87,88
Oxidative stress and inflammatory factors 
Figure 3
Diabetes induces high levels of reactive oxygen species, which are attributable to mitochondrial collapse, and increases the expression of NADPH oxidase, cyclo-oxygenase, lipoxygenase, and carbonyl protein. 
Endothelin-1
Endothelin-1 probably participates in diabetic microvascular complications because blockade of ET A receptors reduces apoptosis in the retina, 109 curtails albuminuria, 63 and restores cerebrovascular function 46, 110 in diabetic mice.
Increased angiogenesis
Serum VEGF concentrations are increased in diabetic patients (Fig. 4) . 111 However, the expression of VEGF varies in diabetic tissues. Thus, in the kidney and retina of diabetic subjects, VEGF expression is elevated. 76 Such increased expression of VEGF is a hallmark of proliferative diabetic retinopathy, and is attributable primarily to local ischemic conditions leading to activation of hypoxia-induced factor (HIF)-1α. 106, 112, 113 However, in the cerebral microvasculature, diabetes reduces VEGF expression, as well as that of its cognate receptors, leading in particular to increased vascular permeability in the hippocampus that explains the deficit in spatial memory. 114 Similarly, VEGF expression is decreased in skin lesions, 115 and diabetic mice with deletion of prolyl hydroxylase domain proteins (PHD; an oxygen sensor that controls HIF degradation) have increased levels of HIF-1α and VEGF, resulting in accelerated recovery of hind limb perfusion. 116 In diabetic cardiomyopathy, VEGF expression is reported to be either increased 117 or decreased. [71] [72] [73] [74] [75] Inhibition of VEGF receptors results in heavy proteinuria in control rats but reduces urinary protein excretion in diabetic rats. 77 Obviously the mechanisms underlying the different patterns of VEGF expression in tissues of diabetic subjects are not fully understood. Local hypoxia, capillary density, and reactions of neighboring cells to the hypoxic conditions are all involved in the pathological process. 
Figure 4
Diabetes induces abnormal angiogenesis in the microvasculature. Local vascular endothelial growth factor (VEGF) levels are increased in the retina and kidneys, but are reduced in skin lesion and in the cerebral vasculature. The abnormal angiogenesis in diabetic retinopathy and nephropathy suggests that diabetes interrupt the coupling between VEGF and nitric oxide (NO). Diabetes reduces angiopoietin (ANGPT) 1, but increases ANGPT2, which destabilizes vascular walls by competing with ANGPT1. In addition, ANGPT2 promotes neovascularization when binding to VEGF.
Vascular endothelial growth factor and NO work together in the process of angiogenesis. In cell culture, VEGF stimulation increases NO production by upregulating eNOS expression in endothelial cells, [118] [119] [120] whereas VEGF-induced angiogenesis is antagonized by N G -nitro-L-arginine methyl ester (L-NAME; an inhibitor of eNOS). 121 In diabetic rats, the number of CD34 + glomerular endothelial cells is increased, which is in line with the upregulation of VEGF, but renal nitrite levels are reduced. 77 The reduced proteinuria caused by blockade of VEGF receptors in diabetic rats is reversed by L-NAME treatment. 77 In diabetic patients with retinopathy, high levels of VEGF are accompanied by eNOS uncoupling and augmented inflammation. 122 The abnormal angiogenesis in diabetic retinopathy and nephropathy is probably due to increased oxidative stress 84 and enhanced expression and/or activity of arginase. 85, 123 Taken together, the available data suggest that diabetes interrupts the coupling between VEGF and NO. 76 Angiopoietins are vascular growth factors, participating in neovascular genesis and blood vessel repair. 124 Angiopoietin (ANGPT) 1 stabilizes the vascular wall, whereas ANGPT2, competing with ANGPT1, destabilizes it 125 by inducing cell apoptosis. 68 In addition, ANGPT2 promotes neovascularization when binding to VEGF. 126 In the porcine kidney and human retina, diabetes reduces the expression of ANGPT1, 124, 127, 128 but increases the expression of ANGPT2, 68, 129, 130 disturbing the balance between the two ANGPTs in favor of the latter. 131, 132 Treatment targeting ANGPTs reduces vascular damage and improves vascular integrity. 127, 133 Angiopoietin-like 4 (ANGPTL4) has beneficial effects on vascular permeability in diabetic retinopathy. 134 This effect of ANGPTL4 is independent of VEGF because anti-VEGF treatment of the retina does not alter the vitreous concentration of ANGPTL4, 135 which thus may represent a new target for the treatment of diabetic microvascular complications.
Endothelial repair in diabetes
Endothelial regeneration is a key mechanism for vascular cell repair and integrity. 136 Circulating growth factors and cytokines derived from mesenchymal and/or stem cells are important for vascular repair because only a few such stem cells home to vascular lesions and differentiate into endothelial cells. 137, 138 Diabetic patients, especially those with vascular complications, have fewer circulating progenitor cells or bone marrowderived hematopoietic cells. [139] [140] [141] [142] More importantly, CD34
+ endothelial progenitor cells exhibit impaired autocrine and paracrine functions in diabetes. 143 Activating the eNOS pathway 144 and reducing AMDA levels 145 restore endothelial progenitor cell functions. Diabetic patients exhibit an altered expression profile of miRNAs involved in angiogenesis, vascular repair, and endothelial homeostasis. VEGF, vascular endothelial growth factor; ANGPT, angiopoietin; NO, nitric oxide.
Hypoxia preconditioning potentiates endothelial progenitor cell treatment in diabetic rats with hind limb ischemia, due to increased expression of VEGF and its receptors. 146 Overexpression of VEGF increases mesenchymal stem cell proliferation, thus facilitating angiogenesis and improving blood perfusion in diabetic rats. 147 
MicroRNAs and diabetic endothelial dysfunction
MicroRNAs are endogenous short, non-coding RNAs consisting of 22 nucleotides. They take part in posttranscriptional regulation of gene expression by binding to the 3 0 untranslated regions of target mRNA sequences, and induce mRNA degradation. 7, 8, 148 Diabetic patients exhibit altered expression profiles of miRNAs involved in angiogenesis, vascular repair, and endothelial homeostasis. 149, 150 (Fig. 5 ). Of these, miRNA-126 is strongly linked with vascular repair. Thus, patients with type 2 diabetes (T2D) exhibit low levels of circulating miRNA-126 compared with healthy subjects;
151,152 restored expression of miRNA-126 in cultured endothelial cells and monocytes, in which it was downregulated by high glucose, reduces tissue factor expression, a major trigger for the coagulation cascade, 151 and overexpression of miRNA-126 promotes the proangiogenic properties of progenitor cells. 152 MicroRNA-195 limits the expression of sirtuin 1 (SIRT1), 153, 154 an NAD-dependent deacetylase that has multiple beneficial effects on age-related diseases, including increased eNOS expression, reduced cell apoptosis, and regulation of glucose metabolism. 155, 156 Silencing miR-195 increases SIRT1 expression and reduces diabetic cardiomyopathy in the mouse. 154 MicroRNA-200b is downregulated in retinal endothelial cells and cardiac microvascular endothelial cells exposed to high glucose, and its overexpression reduces VEGF expression and prevents diabetic retinopathy and cardiomyopathy. 117, 157 MicroRNA-200c is increased in the aorta of T2D mice and the renal arteries of diabetic patients, whereas its overexpression in the aorta of non-diabetic mice increases oxidative stress and impairs endothelium-dependent relaxation. 158 The miRNA-146 family participates in the regulation of oxidative stress and the production of proinflammatory factors. 159, 160 Circulating levels of miR-146a are decreased in diabetic patients; 161 miR-146a downregulates expression of NADPH oxidase 159 and reduces nuclear factor (NF)-κB signalling 162, 163 in endothelial cells exposed to glucose oscillations. In macrophages, miRNA-146b-3p suppresses the expression of adenosine deaminase 2, 160 an important cofactor in the activation of immune responses. 164 Overexpression of either miRNA-146a or miRNA-146b prevents oxidative stress and reduces the production of inflammatory factors in diabetic rodents. 159, 160 Knockdown of miR-185 upregulates glutathione peroxidase-1 protein expression and further increases oxidative stress in endothelial cells when exposed to glucose oscillations. 162 MicroRNA-503 is upregulated in the serum and ischemic limb muscles of diabetic patients. 165, 166 Pericytes in the microvasculature take up this miRNA and reduce their VEGF expression, resulting in increased permeability and impaired post-ischemic angiogenesis in limb muscles; 165, 166 inhibition of miRNA-503 restores endothelial dysfunction and normalizes blood flow recovery in diabetic mice. 165, 166 The miRNAs also play a role in modulating progenitor cell function. In particular, miRNA-130 is involved in cell apoptosis and autophagy. Diabetes downregulates miRNA-130a in endothelial progenitor cells, leading to increased apoptosis and autophagy. 167, 168 In human endothelial cells, high glucose favors the occurrence of apoptosis and this is paralleled by increased expression of several miRNAs (miR-26a-5p, miR-29-a, miR-29b-3p, miR-29c-3p, miR-34-a, miR-103, miR-107, miR-125b-1-3p, miR-132, miR-140-5p, miR-142-3p, miR-144, miR-192-5p, miR-221-3p, and miR320a). 158 In brief, several microRNAs have exhibited potential in curtailing endothelial dysfunction in diabetic animals, showing promise for future antidiabetes treatment. Nevertheless, caution is required before identifying circulating microRNAs as biomarkers for the early diagnosis of diabetes-induced endothelial dysfunction, because diabetes mellitus is a heterogeneous disorder that widely affects microRNA expression beyond endothelial cells. 169 
Metabolic memory
Metabolic memory in diabetes is characterized by longlasting deleterious effects of previous exposure to hyperglycemia that are not restored by correction of blood glucose levels. 17, 170 In both T1D patients and healthy controls, hyperglycemia following hypoglycemia favors the activation of thrombosis and oxidative stress. 171 Patients with T2D and chronic heart disease exhibit enhanced blood glucose fluctuations, a phenomenon that is significantly correlated with blunted endothelium-dependent, flow-mediated dilatations in their brachial arteries. 172 The underlying mechanisms include enhanced oxidative stress, the formation of advanced glycation end-products, epigenetic modification, and chronic inflammation. 173 In cultured endothelial cells, the metabolic memory-induced blunted endothelial response has been attributed to increased oxidative stress, which is derived from uncoupled eNOS 174 and/or mitochondria.
17,175
Epigenetic changes
In contrast with genetic modifications, epigenetic changes are susceptible to modifications by the environment as well as dysregulation over time; DNA methylation, histone modification, and non-coding RNA are three major types of epigenetic effects. 176 We are not aware of studies specifically examining epigenetic modulation of endothelial function in diabetes. Indeed, most studies involving epigenetic changes in diabetes collect samples (serum, blood cells, skeletal muscle, adipose tissue, or pancreatic islets) from diabetic patients and compare the data with data from normal subjects. A meta-analysis combining 47 studies did not reveal a general overlap of epigenetic changes on any specific genes, although each individual study has reported several interesting candidates. 177 Obviously larger-scale and prospective investigations are needed to establish whether epigenetic changes affect the risk of developing diabetes in general, and endothelial dysfunction in particular. 177 
Antidiabetes treatment
Although exogenous insulin remains a therapy of choice, in particular in T1D patients, several alternative therapies have possible implications for preventing or curing endothelial dysfunction (and thus diabetic morbidity and mortality) because they correct the disturbances summarized above. But this is not always the case for several reasons, as outlined below. 1. Because endothelium-derived NO plays a critical role in vascular biology and its bioactivity is curtailed in the blood vessels of diabetic patients, protecting the latter is beneficial. Coenzyme Q10 supplementation reduces AMDA levels and decreases diabetic cardiovascular events. 178 Inhibition of arginase improves endothelial dysfunction in T2D patients. 179 Metformin improves angiogenic functions of endothelial and endothelial progenitor cells by stimulating the eNOS pathway. [180] [181] [182] 2. Considering the elevated ROS levels in diabetes in general and the resulting endothelial dysfunction in particular, it would seem reasonable to treat diabetic patients with antioxidants. Indeed, antioxidants reverse visual decline, 90 preserve cerebral barrier integrity, 183 and reduce left ventricular mass 184 in small groups of diabetic patients. Transdermal deferoxamine treatment accelerates diabetic wound healing and prevents ulcer formation by preventing ioncatalysed reactive oxygen stress, 185 suggesting that local administration of antioxidants is probably of value for diabetic patients with skin lesions. However, a meta-analysis of 68 randomized trails revealed that chronic treatment with antioxidants such as vitamin A, vitamin C, vitamin E, β-carotenes, or selenium has no significant beneficial effect on vascular mortality in diabetes patients. 186 This could be accounted for by high levels of antioxidant supplements in the current normal diet and/or inhibitory effects on endogenous antioxidants by exogenous treatment. 187, 188 3. Although serum levels of VEGF are increased in diabetic patients, the tissue distribution of VEGF is uneven. Many diabetic patients with proliferative retinopathy have high circulating levels of VEGF but do not respond well to intravitreal anti-VEGF treatment. 189 4. Cilostazol, a selective inhibitor of phosphodiesterase-3, possesses vasodilator properties and has antiinflammatory effects. In diabetic patients, cilostazol reduces soluble CD40 ligand 190 and thrombomodulin 191 levels in the serum, leading to a reduction of restenosis after percutaneous transluminal coronary angioplasty. 192 Cilostazol also improves the function of circulating endothelial progenitor cells in diabetic patients with ischemic cerebrovascular disease. 193 The protective effects of cilostazol are attributable to upregulation of peroxisome proliferator-activated receptor (PPAR) γ 194 and eNOS, 195, 196 downregulation of VCAM, 197 or blockade of the TNF pathway.
102,103
5. Glucagon-like peptide-1 (GLP-1) and its analogs are generated in neuroendocrine L-cells in the ileum after a meal, stimulating insulin release and inhibiting glucagon release, which elevate serum glucose levels. 198 Inhibitors of dipeptidyl peptidase-4 (DDP-4) increase GLP-1 levels by preventing the degradation of GLP-1 by DPP-4. 198 In addition to glucose regulatory effects, GLP-1, and thus DDP inhibitors, have direct protective effects on the cardiovascular system. Glucagon-like peptide-1 protects barrier integrity in primary cultured brain endothelial cells, 199 reduces cardiac microvascular injury, 200 and inhibits AMDA generation in the kidneys of diabetic rats. 201 Inhibition of DDP-4 prevents diabetesinduced endothelial barrier breakdown in the rat retina, 56 reduces oxidative stress in rats with diabetic nephropathy, 202, 203 attenuates neointima formation, and potentiates endothelial regeneration after vascular injury in diabetic rodents. [204] [205] [206] In small groups of diabetic patients, treatment with a DDP-4 inhibitor increased circulating endothelial progenitor cells. 207 and reduced plasma markers of inflammation, such as IL-6 and C-reactive protein. 208 6. Appropriate physical training increases eNOS expression 209 and reduces oxidative stress, 210 thus improving vasodilatation 211 and skin lesion healing in diabetic mice. 212 Similarly, exercise training improves vascular function in diabetic patients. 213 
Conclusion
Endothelial dysfunction, especially at the level of the microvasculature, is one of the most deleterious events in diabetes. Reduced NO bioavailability, increased oxidative stress, an imbalance between VEGF and NO, and impairment of endothelial repair are the main culprits leading to such dysfunction. Because of the better understanding of the mechanisms underlying diabetes, new treatments have been proposed for clinical practice. However, some of them work well in animal models, but not really in patients. Treatments targeting miRNAs, specifically those interfering with the balance between VEGF and NO and endothelial progenitor cell function, may be promising avenues to therapeutically address endothelial dysfunction in diabetes. 
